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ABSTRACT
THE ROLE OF SRC IN NSCLC CELL AND LUNG FIBROBLAST MIGRATION
ON 3D CELL-DERIVED MATRIX
Austin M. Krueger
April 13, 2021
Lung cancer is responsible for the most cancer deaths between males and
females, with a 6% five-year survival rate. Cancer metastasis is one of the
leading causes of lung cancer lethality. Our lab has developed a method to
culture cells on cell-derived matrix (CDM) and study cell-ECM interactions. This
study utilized multiple cell migration methods to investigate the migration of
NSCLC cells and IMR90 lung fibroblasts, both together and independently, on 2D
plastic and 3D CDM. Our results showed that inhibiting Src, a significant
influencer of cell migration and member of integrin activation, blocked cancer cell
migration on 2D and 3D CDM, regardless of interactions with fibroblasts or not.
However, when IMR90 lung fibroblasts were treated with a Src inhibitor,
migration decreased on 2D but not on 3D. These results suggest that cancer
cells migrate in a Src-dependent manner on 3D CDM, but IMR90 lung fibroblasts
do not.
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INTRODUCTION
Lung Cancer
Lung cancer is the leading cause of cancer deaths among males and
females, accounting for the second most common type in both sexes in the United
States [1]. Not only does lung cancer account for the most deaths, but it is also
more fatal than colon, breast, and prostate combined [1]. There are two
classifications of lung cancer: small cell and non-small cell [1, 2]. Small cell lung
cancer accounts for an estimated 15% of lung cancer cases [2]. However, small
cell lung cancer is more deadly than non-small cell lung cancer, with a 6% 5-year
survival rate [2]. Non-small cell lung cancer (NSCLC) is further classified into three
groups: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
Adenocarcinoma is not only the most common cancer type worldwide but also the
most common cancer type of NSCLC, accounting for more than 40% of incidences.
It is evident that lung cancer poses a significant hurdle in cancer research today,
but what is causing it?
Lung Cancer Metastasis
The National Cancer Institute defines metastasis as "the spread of cancer
cells from the place where they first formed to another part of the body." The
metastatic spread of cancer accounts for approximately 90% of cancer deaths [3].
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Traditionally, a lung cancer patient may not observe significant symptoms until the
disease has reached a later stage involving metastasis. If a patient is first
diagnosed with lung cancer that metastasized to distant regions (regions other
than the lung and tissues surrounding the lung), their chance to survive more than
5 years is 6% [1]. It is evident that most lung cancer deaths are due to metastasis
and detecting the disease too late. Although several lung cancer prevention
methods (screening, healthy diet/lifestyle, and avoiding smoking), there is still a
considerable need to treat those with metastatic lung cancer.
Cancer metastasis can be divided into four separate stages: invasion and
intravasation, circulation, extravasation, and metastatic colonization [3]. The first
step in cancer metastasis is the cancer cells gaining enough mutations and tumor
microenvironment (TME) cues to invade through the tissue's basement membrane
[3]. Once they have invaded through the basement membrane, cancer cells can
enter the patient's blood circulation. In animal models, approximately 0.01% of
cancer cells survive in the host's blood circulation [4]. Because cancer cells are
genetically unstable, the small percentage of cancer cells that remain in the host's
circulation blood could extravasate. Following extravasation, the cancer cell may
form a metastatic colony in another part of the body. So, how does one target
cancer cell metastasis?
Tumor Microenvironment
The TME is an emerging topic in metastatic cancer research. Composed of
numerous cell types, the TME plays a vital role in cancer cell survival, proliferation,
and metastasis [5]. The primary cell types of the TME are cancer cells, epithelial
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cells, endothelial cells, fibroblasts, cancer-associated fibroblasts, and a plethora of
immune cells [6]. Some non-cell components are the extracellular matrix (ECM),
cytokines (growth factors, chemokines, etc.), and secreted proteins [6]. Targeting
cancer metastasis has proven to be difficult. One possible reason is that many in
vitro studies do not take the ECM into account. To investigate the interaction of
NSCLC cells and the ECM, the entire TME must be considered.
Of the cellular components of the TME, fibroblasts perform critical functions
in the interaction between cancer cells and the ECM. The major ECM secreting
cell type in the body is fibroblasts [6]. Additionally, fibroblasts are responsible for
secreting growth factors and other proteins involved in ECM remodeling [6]. An
exciting topic in cancer research is investigating cancer-associated fibroblasts
(CAFs). CAFs are commonly derived from tissue-resident fibroblasts and induced
by components of the TME. Numerous studies show the different effects CAFs
have on the TME as opposed to non-CAFs [7]. Among those differences are
growth factor and cytokine secretions, as well as ECM remodeling [8]. Together,
the impact of fibroblasts on the TME is vital in the ECM-cancer cell interplay.
The Extracellular Matrix Environment
The ECM contains many different compartments connecting the cell with
the surrounding environment and impacting the cell on many different levels. The
major structural components of the ECM are collagen, proteoglycans, laminin, and
fibronectin [9]. Collagens are the most abundant proteins in the human body,
comprising nearly 30% of tissue mass, including 28 different subtypes [10].
Collagens lay the foundation for the architecture of the ECM. Proteoglycans are

3

composed of several subtypes. Perlecan, hyalecan, and small leucine-rich
proteoglycan (SLRP) are the main proteoglycans that make up the ECM [9]. They
play roles in collagen-fibronectin and collagen-collagen connections acting as the
"glue" to hold the ECM together [11]. Laminins are made up of alpha, gamma, and
delta chains comprising 16 different combinations. They are responsible for
connecting the cell to the ECM [9]. Lastly, fibronectin is a multi-domain protein that
interacts with the previous structural components discussed. Through these
interactions, fibronectin provides connecting points for the cell and ECM. Each
structural element of the ECM plays a unique role in the cancer cell-ECM
interaction.
Embedded in the ECM are multiple types of ligands, including growth
factors, chemokines, and other cytokines proteins, as well as proteases
responsible for degrading the ECM [12]. Essential growth factors are tumor growth
factor-ß, interleukins, insulin-like growth factors, and epithelial growth factor [13].
Matrix metalloproteases play a critical role in ECM degradation, providing space
for the cell to move through [14]. Each part of the ECM environment is involved in
the ECM-cell interaction.
Aside from the external compartments, there is a copious number of
components integrated into the cell membrane. Of these, integrins are one of the
most critical transmembrane proteins involved in ECM-cell interactions. They
contain an alpha and beta subunit, composing 24 known heterodimers with
individual functions [15]. Binding to the ECM through collagen, laminin, and
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fibronectin, integrins provide a crucial cell connection to the ECM [16]. Their
functions in cell invasion, adhesion, and migration are well documented.
AlphaV-Beta3 and Alpha5-Beta1 integrins, specifically, lead to focal
adhesion kinase (FAK), Src family kinase (SFK) signaling activation, and eventual
ERK, JUN, and Rac signaling activation [17]. When the integrins interact with the
structural components and ligands of the ECM, the intracellular beta domain is
activated by MRL proteins (MIG-10, RIAM, and Lamellipodin) [18] and recruits talin
to promote actin polymerization and integrin clustering [16]. Integrin clustering
ensures FAK and SFK activation. FAK/SFK and their downstream activation play
one of the most critical roles in cell adhesion and movement.
Epithelial to Mesenchymal Transition
The

Epithelial

to

Mesenchymal

Transition

(EMT)

describes

the

transformation of epithelial-like cells to mesenchymal state [19]. An "epithelial-like"
cell's rectangular shape will transition into a spindle-like, mesenchymal shape [20].
The transformation induces the cell to behave more stem-like, increasing its
invasive and migratory phenotypes [19]. EMT contains a highly complex network
of signaling to induce the mesenchymal states. The primary EMT inducers are
TGF-beta, Wnt, Notch, hypoxia, PIK3, JAK/STAT, and integrin activation [21].
These pathways lead to the activation of critical EMT transcription factors: Snail 1,
Slug, ZEB1/2, and Twist [21]. The transcription factors suppress the expression of
crucial epithelial transition signalings, such as E-cadherin, occludins, claudins, and
cytokeratins. N-cadherin, Vimentin, fibronectin, and MMPs are upregulated by the
EMT transcription factors [19]. Not only do integrin-mediated FAK/SFK signaling
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and MMP activity play a critical role in cell-ECM interaction and remodeling, but
they also are integral members of EMT.
The interaction between the cell and the extracellular matrix plays a vital
role in cancer cell metastasis through external cues, such as ligand binding and
integrin activation. Ligands embedded in the ECM and mutations acquired by
cancer cells induce EMT through receptor-mediated activation. For example, TGFbeta, which is secreted by multiple cell types, induces EMT through the activation
of SMAD2/3 and RAS/MAPK/ERK induction of EMT transcription factors [19].
Additionally, integrin activation induces FAK/SFK signaling to activate RAS, PI3K,
STAT signaling, and EMT transcription factors [19]. Lastly, SNAIL1 and ZEB2
moderated the activation of MMPs responsible for ECM degradation [19]. How can
one phenotypically show that alterations of these interactions influence cancer cell
phenotype?
Cell Migration and Invasion
The ECM plays a crucial role in cell migration and invasion through
alterations in signaling cascades related to EMT. Considering cancer metastasis
steps, studying the invasion and migration of cancer cells in vitro can help
researchers target cancer cell migration mechanisms from the primary tumor site.
Four in vitro approaches to studying cancer cell migration are spheroid, scratch
would, individual cell tracking, and trans-well assays:
1. A spheroid assay can be performed by culturing cancer cells in a nonadherent, round bottom 96-well plate long enough for the cells to form a
spherical structure, the "spheroid" [22]. The spheroid is transferred to
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another plate, and the migration of cells from the spheroid can be monitored
over time. This assay is a measure of collective cell migration. Using
ImageJ, a software provided by the NIH, the migration of cells can be
quantified by defining the area of which the cells have migrated away from
the core of the spheroid.
2. A scratch wound assay can be performed by creating a wound in a confluent
cancer cell monolayer [23]. Once the wound is made, the collective
migration of cells to close the wound can be monitored over time. Using
ImageJ, a software provided by the NIH, the migration of cells can be
quantified by defining the area of which the cells have migrated into the
wound. This may be referred to as the wound closure.
3. One may also monitor individual cell migration by individually tracking
cancer cells' velocity and directionality over time [24]. This may be done by
adding a low concentration, single-cell suspension, to a cell culture plate.
The cells are monitored over time using live-cell imaging and utilizing
available cell tracking softwares.
4. A trans-well assay is performed by culturing cancer cells in nutrient-free
media on top of a Boyden chamber. The Boyden chamber contains small
pores wide enough for single cells to fit through [25]. On the other side of
the pore is media containing nutrients and other factors to attract the cancer
cells [25]. One can then quantify the number of cells that migrated through
the pores over time by quantifying the number of cells attached to the
bottom of the cell culture plate.
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Together, these four assays allow researchers to study cancer cell migration from
many different angles.
A critical step in cancer metastasis is cancer cells breaking through the
basement membrane and out of the primary tumor site to other sites in the body.
Invasion assays are very similar to migration assays except for one added
component: Matrigel. Matrigel is a gel-like substance at room temperature that can
act as a basement membrane and is comparable to embryonic basement
membranes [26]. In-depth proteomic analysis shows the key components of
Matrigel are laminin-1, collagen IV, entactin, and heparan sulfate proteoglycan,
which provide both structural support and comparable signal transduction to the
embryonic basement membrane/ECM [27]. With Matrigel, researchers can modify
migration assays into invasion assays:
1. Adding Matrigel to the non-adherent well containing the spheroid
encapsulates the spheroid with the gel-like substance [22]. Cells then
invade into the gel surrounding the spheroid as well as away from the
spheroid itself. Using ImageJ, a software provided by the NIH, the migration
of cells can be quantified by defining the area of which the cells have
migrated away from the core of the spheroid.
2. In a scratch wound assay, the addition of a thin monolayer of Matrigel to
the top of the cells overlays the wound made. This allows the cells to invade
into the wound [28]. Using ImageJ, a software provided by the NIH, the
migration of cells can be quantified by defining the area of which the cells
have migrated into the wound.
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3. By creating a 1:1 ratio of low concentrated, single-cell suspension and
Matrigel, one can add the mixture to a cell culture plate. Because the cells
are encapsulated in Matrigel, cells are forced to invade through the gel-like
substance [24]. The cells are monitored over time using live-cell imaging
and utilizing available cell tracking softwares.
4. Adding a layer of Matrigel to the Boyden chamber pores would force the
cells to invade through the Matrigel to reach the nutrient-filled media below
[29]. One can then quantify the number of cells that migrated through the
pores over time by quantifying the number of cells attached to the bottom
of the cell culture plate.
Using these techniques, researchers can study cancer cell invasion in vitro.
The World Health Organization reported approximately 10 million people
die from cancer each year. As one of the leading causes of death worldwide,
cancer research is crucial in finding better treatments for cancer patients. Because
cancer metastasis is responsible for a worse 5-year survival rate, investigating
cancer cell migration and invasion may provide helpful information to design drugs
to target cancer metastasis. There are multiple assays to study cancer cell
migration and invasion, each with its own positive and negative characteristics.
Choosing which assay to use will depend on a researcher's available technology
and time.
Cell-Derived Matrices
Knowing that the ECM plays a pivotal role in cancer cell migration and
invasion, how do researchers apply this concept to the previously discussed
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migration and invasion assays? Utilizing fibroblasts' ability to produce a surplus of
extracellular matrix, one can culture fibroblasts long enough to deposit a layer of
ECM on a cell culture plate. Once the fibroblasts decellularized from the plate, a
layer of ECM is left behind. Researchers can then seed cells on top of the ECM
layer and study the cell's interaction with the ECM [30].
The most apparent difference between cells cultured on 3D CDM and 2D
plastic is the cell phenotype. To perform various migration and invasions assays
using 3D CDM, one would perform the assay the same way except that the cells
are cultured on 3D CDM. Cells naturally shaped like a cube in standard 2D culture
methods appear more elongated and spindle-like in a 3D CDM environment [28].
With this phenotype, researchers studied the signaling differences in cells cultured
in a 3D CDM system. Remarkably, the differences were incredibly obtuse. EMT
markers were increased in cells cultured on 3D CDM, and the proliferation,
migration, and invasion of cancer cells were significantly different [30]. Specifically,
epithelial markers were decreased, and mesenchymal markers were increased in
cells cultured on 3D CDM [30]. FAK/SFK signaling is also affected. Phenotypically,
proliferation is slightly decreased while migration and invasion are increased [30].
Culturing cells on 2D plastic as opposed to 3D CDM yields different phenotypes
and cancer cell signaling.
Cell-derived matrices (CDMs) impact cells in many ways, and the
technique is well documented and highly reproducible [28] [30] [31]. It is
postulated that culturing cells on ECM is a more physiologically relevant model
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for cancer research in vitro. Using 3D CDM culture techniques may yield more
consistent in vitro results.
ECM Remodeling
Velocity and displacement increased significantly in NSCLC cells cultured
on 3D CDM [30]. An important distinction between 3D CDM and 2D plastic is the
physical appearance. Expectedly, 2D plastic looks flat and appears smooth. 3D
CDM seems more rigid and gelatinous. Using light microscopy, one can see the
collagen fibers of the ECM are aligned in a web-like network. As a whole, the
CDM may seem unorganized; however, the CDM's rigidity is what provides
directionality to the cells. Cell-derived ECM provides a road network for cells
cultured on CDM. Cancer cells react to the framework the CDM provides.
Fibroblasts are the central regulators of the tumor ECM environment [32].
They are responsible for secreting soluble actors, ECM remodeling, metabolic
effects, and immune crosstalk and secrete many different soluble secretory
factors, such as VEG-F and TGF-Beta [32]. They remodel the ECM through
matrix crosslinking, proteolysis, and matrix production [32]. Metabolic effects
include lactate shuffling (providing lactate to cancer cells dependent on such for
energy) and amino acid shuffling [32]. Lastly, fibroblasts interact with surrounding
immune cells through TGF-Beta and IL-6 activation and CCL2 production. The
interaction between cancer cells and fibroblasts is synergistic, meaning
fibroblasts can prime cancer cells for invasion/migration, and cancer cells can
induce an activated phenotype of fibroblasts.
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It is thought that there are three resting states of fibroblasts: resting,
normal-activated, and fibrosis/cancer-associated [33]. Fibroblasts are typically
found in a resting form where surrounding stimuli can activate them to normalactivated fibroblasts. In their resting state, fibroblasts are spindle-shaped, do not
migrate, produce ECM, or secrete soluble factors [33]. Normal-activated
fibroblasts are identified primarily through alpha-SMA and vimentin expression
[33]. This transition is reversible through genetic reprogramming and induction of
apoptosis. Normal-activated fibroblasts play a considerable role in wound healing
and fibrosis. From the normal activated state, fibroblasts can transition into
fibrosis- or cancer-associated fibroblasts through epigenetic regulation. One key
identifiable marker is fibroblast activation protein expression. The critical
difference between the two states is that cancer-associated fibroblasts proliferate
more, secrete more growth factors, and do not produce as much ECM [33]. Once
fibroblasts are in this state, they cannot revert to normal-activated fibroblasts.
It is apparent that taking into account multiple members of the TME is
increasingly vital in studying cancer cell migration and invasion. Our study aimed
to investigate the interaction between cancer cells, fibroblasts, and the ECM
independently and co-dependently. Our results suggest that NSCLC cells and
fibroblasts migrate through different migration mechanisms on 3D cell-derived
matrix, where they migrate through similar mechanisms on 2D. This information
is critical in elucidating the methods by which the TME impacts cancer cell
migration.
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MATERIALS AND METHODS
Cell culture
Human normal fetal lung fibroblast cell lines WI38, IMR90, and CCL-201 were
purchased from American Type Culture Collection (ATCC) and maintained in
Minimum Essential Medium Alpha modification (MEM-α) supplemented with LGln, ribo- and deoxyribonucleosides (Fisher),10% fetal bovine serum (Invitrogen)
and 1% antibiotic/antimycotic (Sigma). Human mesenchymal cell lines (WI38 and
IMR90) were performed with early passage cells (p < 8) in the same culturing
medium, MEMα, described previously. A549, H2009, and H2030 human
adenocarcinoma cells were purchased from ATCC and were cultured in RPMI
medium supplemented with 10% FBS and 1% antibiotic. All cell lines were
maintained at 37ºC and 5% CO2, unless otherwise stated.
Extracellular Matrix Preparation
Extracellular matrix preparation was performed as previously described [30].
Briefly, IMR90, WI38, or CCL-201 lung fibroblasts were plated at confluence in
matrix
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growth medium (MEM-α, 10% FBS, 1% antibiotic). On the second, fourth, and
sixth days, medium was supplemented with 50 µg/mL L-Ascorbic acid (Sigma) to
promote matrix deposition. On the eighth day, wells were washed with phosphate
buffered saline (PBS), and cells were lysed with a detergent (20mM NH4OH,
0.05% Triton-X-100) for 1-3 minute incubation at 37º C until complete cell lysis
was observed. The resulting cell-derived matrices were gently washed three
times with PBS and then incubated with Dnase1 (10 U/mL) for 30-60 minutes to
remove residual DNA. The matrices were then washed twice in PBS and either
used immediately or stored at 4ºC in PBS supplemented with 1% antibiotic for up
to 4 months.
Microscopy
Live-cell time-lapse phase and fluorescence microscopy were performed using a
Keyence All-in-One Fluorescence Microscope (BZ-X series).
Scratch Wound Migration Assay
Lung cancer cells were plated at confluence and serum-starved overnight
following attachment. A micropipette tip was used to create a scratch in the cell
monolayer, and pictures were captured at the indicated time points. 3D invasion
assays were plated using a WI38 derived matrix that had not been supplemented
with ascorbic acid during the growth. Ascorbic acid supplementation or use of
IMR90 fibroblast matrices results in a matrix that was too thick to scratch reliably.
Images were captured at the indicated timepoints. Results were quantified using
the area measurement of imageJ, comparing the wound closure at the time of
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the image to the initial wound. Averages of at least three images were captured
for each time point, and at least two replicates were used for each experiment.
Spheroid Preparation
Lung cancer cells were culture under normal conditions on a Corning ultralow
attachment 96 well plate (Sigma) at 1x104 cells per well for 4 days to allow small,
rounded spheroids. Spheroids were observed under microscopy and transferred
to matrix plates with a micropipette for further migration studies.
Western Blot
Cells and tissue samples were harvested in CHAPS lysis buffer (1% CHAPS
detergent, 150mM NaCl, 50mM Tris pH7, 5mM EDTA) supplemented with
complete protease inhibitor and PhosSTOP phosphatase inhibitor cocktail tablets
(Sigma-Aldrich, St. Louis, MO). Total protein (40µg) was heated at 95ºC for 5
minutes and separated by 4-12% SDS-polyacrylamide gel. Blots were transferred
to PVDF membranes for 120 minutes at a constant voltage of 100 V in 4ºC.
Membranes were blocked in 5% milk (w/v) in Tris-buffered saline Tween-20
(TBS-T) at 24ºC for 1 hour. The membranes were incubated with the primary
antibody in 5% milk TBS-T overnight at 4ºC. A list of antibodies used for analysis
is presented in the supplementary material.
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Antibody

Host

Catalog

Distributor

Src

Rabbit

#2108

Cell Signaling Technologies

P-Src Family (Tyr416)

Rabbit

#2101

Cell Signaling Technologies

FAK (D2R2E)

Rabbit

#13009

Cell Signaling Technologies

P-FAK (Tyr397) (D20B1)

Rabbit

#8556

Cell Signaling Technologies

GAPDH (D16H11)

Rabbit

#5174

Cell Signaling Technologies

Rabbit IgG HRP

Goat

#7074

Cell Signaling Technologies

Table 1. Antibodies.
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Statistics
Student's t-tests were used for comparisons between two groups. A one-way
ANOVA with Tukey's test for multiple comparisons was used to determine
statistical significance for multiple groups, unless otherwise stated. Statistical
significance was considered for P-value < 0.05.
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RESULTS
Non-small cell lung cancer cell migration increases on 3D cell-derived
matrix.
We have previously shown that cancer cell signaling and proliferation change on
the 3D cell-derived matrix [30]. To investigate how culturing cells on 3D cellderived matrix influences cell migration, we examined spheroid spreading on 2D
plastic and 3D IMR90-derived matrix. Hop62 non-small cell lung cancer (NSCLC)
cell spheroids were cultured on 2D plastic and 3D IMR90-derived matrix for 48
hours (Figure 1a). The migrational area of the spheroids was measured and
quantified via ImageJ. Hop62 spheroids cultured on 3D migrated significantly
more than the spheroids cultured on 2D (Figure 1b).
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Figure 1. Collective cell migration increases in Hop62 lung cancer cells on
3D.
Hop62 spheroids were grown for four days and transferred to 2D plastic, and 3D
IMR90 derived ECM. A) Schematic of Spheroid Migration Assay. B) Images were
captured at 0 and 48 hours after initial plating. C) Quantification of total migrated
area relative to the area of the spheroid. Statistical analysis performed by
unpaired T-test was performed, ** p<0.01; Data presented as mean ±S.E.M.
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H2030 NSCLC cell spheroids were cultured on 2D plastic and 3D IMR90-derived
matrix for 48 hours (Figure 2a). The migrational area of the spheroids was
measured and quantified via ImageJ. H2030 spheroids cultured on 3D migrated
significantly more than the spheroids cultured on 2D (Figure 2b).
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Figure 2. Collective cell migration increases in H2030 lung cancer cells on
3D.
H2030 spheroids were grown for four days and transferred to 2D plastic, and 3D
IMR90 derived ECM. A) Images were captured at 0 and 48 hours after initial
plating. B) Quantification of total migrated area relative to the area of the
spheroid. Statistical analysis performed by unpaired T-test was performed, ***
p<0.005; Data presented as mean ±S.E.M.
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Because migration was increased on 3D, we wanted to investigate whether the
type of matrix mattered. Hop62 spheroids were cultured on 2D, 3D IMR90
derived matrix, and 3D CCL-201 (adult lung fibroblast) derived matrix for 48
hours (Figure 3a). The migrational area of the spheroids was measured and
quantified via ImageJ. Hop62 spheroid migration increased on 3D compared to
2D regardless of the matrix type (Figure 3b).
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Figure 3. Collective cell migration of Hop62s increase on 3D regardless of
the type of ECM used.
Hop62 spheroids were grown for four days and transferred to 2D plastic and
multiple 3D cell-derived ECM. B) Images were captured 48 hours after initial
plating. A) Quantification of total migrated area relative to the area of the
spheroid. Statistical analysis performed by 1-way ANOVA was performed with
multiple comparisons; *** p<0.005; Data presented as mean ±S.E.M.
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To investigate whether the phenotype was dependent on the migrational as
performed, a scratch wound migration assay was performed with A549 NSCLC
cells on 2D plastic and 3D IMR90 derived matrix (Figure 4a). The relative wound
closures were recorded at 6, 24, and 48 hours and quantified via ImageJ. The
wound closure was significantly increased on 3D compared to 2D at all time
points (Figure 4b). These data suggest that NSCLC cells migrate more on 3D
compared to 2D.
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Figure 4. Relative wound closure is increased in A549 lung cancer cells on
3D.
A549 cancer cells are grown on 2D or 3D CDM at confluence, and a scratch
wound is created. The excellent area is then either overlaid with complete media.
A) Images were captured at 0, 6, 24, and 48 hours. B) Quantification of the
relative wound area. Statistical analysis performed by unpaired t-test was
performed, ** p<0.01, *** p<0.005; Data presented as mean ±S.E.M.
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Src inhibition blocks NSCLC migration.
It had previously been shown that integrin signaling is altered in A549 cancer
cells cultured on 2D compared to 3D cell-derived matrix [30]. It is well
documented that Src plays a pivotal role in integrin signaling and cell migration
[17, 34, 35]. To investigate the role of Src, an Src inhibitor (Saracatinib) was used
to inhibit Src phosphorylation in Hop62, H2030, and A549 NSCLC cells. To
determine the concertation of Saracatinib that was not lethal to Hop62 cells, an
Alamar Blue cell viability assay with varying concentrations (0-20µM) of
Saracatinib at 24, 48, and 72 hours was performed (Figure 5a). Next, Hop62
cells were cultured on 2D and 3D with varying concentrations of Saracatinib (010µM) to determine which concertation inhibits Src phosphorylation (Figure 5b).
In Hop62 cells, saracatinib significantly inhibited Src phosphorylation at the 10µM
range on 2D and the 5-10µM range on 3D (Figure 5b).
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Figure 5. Saracatinib inhibits Src phosphorylation in Hop62 lung cancer
cells.
Hop62 cells were treated with varying concentrations of Saracatinib. A) Alamar
Blue readings were recorded 24, 48, and 72 hours following treatment. B) Hop62
cells were plated on 2D, and 3D IMR90 derived matrix. The cells were treated
with varying concentrations of Saracatinib and collected 72 hours following
treatment. Western blot analysis of the extracts was probed for p-src, src, and
GAPDH.
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To determine the concertation of Saracatinib that was not lethal to A549 cells, an
Alamar Blue cell viability assay with varying concentrations (0-20µM) of
Saracatinib at 24, 48, and 72 hours was performed (Figure 6a). Next, A549 cells
were cultured on 2D and 3D with varying concentrations of Saracatinib (0-10µM)
to determine which concertation inhibits Src phosphorylation (Figure 6b).
Saracatinib significantly inhibited Src phosphorylation from the 0.6-10µM range in
A549 cells on both 2D and 3D (Figure 6b).
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Figure 6. Saracatinib inhibits Src phosphorylation in A549 lung cancer
cells.
A549 cells were treated with varying concentrations of Saracatinib. A) Alamar
Blue readings were recorded 24, 48, and 72 hours following treatment. B) A549
cells were plated on 2D, and 3D IMR90 derived matrix. The cells were treated
with varying concentrations of Saracatinib and collected 72 hours following
treatment. Western blot analysis of the extracts was probed for p-src, src, and
GAPDH.
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To determine the concertation of Saracatinib that was not lethal to H2030 cells,
an Alamar Blue cell viability assay with varying concentrations (0-20µM) of
Saracatinib at 24, 48, and 72 hours was performed (Figure 7a). Next, H2030
cells were cultured on 2D and 3D with varying concentrations of Saracatinib (010µM) to determine which concertation inhibits Src phosphorylation (Figure 7b).
In H2030 cells, saracatinib significantly inhibited Src phosphorylation at the 1.2510µM range on 2D and the 2.5-10µM range on 3D (Figure 7b).
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Figure 7. Saracatinib inhibits Src phosphorylation in H2030 lung cancer
cells.
H2030 cells were treated with varying concentrations of Saracatinib. A) Alamar
Blue readings were recorded 24, 48, and 72 hours following treatment. B) H2030
cells were plated on 2D, and 3D IMR90 derived matrix. The cells were treated
with varying concentrations of Saracatinib and collected 72 hours following
treatment. Western blot analysis of the extracts was probed for p-src, src, and
GAPDH.
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To assess the inhibition of Src's effect on cancer cell migration, spheroid assays
were performed on 2D and 3D with multiple lung cancer cell lines and treated
with Saracatinib or not. Hop62 cell spheroids, treated with 5µM of Saracatinib or
a DMSO vehicle control, were cultured on 2D plastic and 3D IMR90-derived
matrix for 48 hours (Figure 8a). The migrational area of the spheroids was
measured and quantified via ImageJ. Hop62 spheroids treated with Saracatinib
migrated significantly less on 2D and 3D compared to the vehicle control (Figure
8b).
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Figure 8. Saracatinib blocks the collective migration of Hop62 lung cancer
cells.
Hop62 spheroids were grown for four days and transferred to 2D plastic, and 3D
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B)
Quantification of total migrated area relative to the area of the spheroid.
Statistical analysis performed by 2-way ANOVA was performed with multiple
comparisons, *** p<0.005, **** p<0.001; Data presented as mean ±S.E.M.
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A549 cell spheroids, treated with 5µM of Saracatinib or a DMSO vehicle control,
were cultured on 2D plastic and 3D IMR90-derived matrix for 48 hours (Figure
9a). The migrational area of the spheroids was measured and quantified via
ImageJ. A549 spheroids treated with Saracatinib migrated significantly less on
2D and 3D compared to the vehicle control (Figure 9b).
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Figure 9. Saracatinib blocks the collective migration of A549 lung cancer
cells.
A549 spheroids were grown for four days and transferred to 2D plastic, and 3D
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B)
Quantification of total migrated area relative to the area of the spheroid.
Statistical analysis performed by 2-way ANOVA was performed with multiple
comparisons, **** p<0.001; Data presented as mean ±S.E.M.
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H2030 cell spheroids, treated with 5µM of Saracatinib or a DMSO vehicle control,
were cultured on 2D plastic and 3D IMR90-derived matrix for 48 hours (Figure
8a). The migrational area of the spheroids was measured and quantified via
ImageJ. H2030 spheroids treated with Saracatinib migrated significantly less on
2D and 3D compared to the vehicle control (Figure 10b).
These data support that inhibiting Src phosphorylation blocks migration of
NSCLC cell spheroids regardless of being cultured on 2D plastic or 3D cellderived matrix.
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Figure 10. Saracatinib blocks the collective migration of H2030 lung cancer
cells.
H2030 spheroids were grown for four days and transferred to 2D plastic, and 3D
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B)
Quantification of total migrated area relative to the area of the spheroid.
Statistical analysis performed by 2-way ANOVA was performed with multiple
comparisons, ** p<0.01, **** p<0.001; Data presented as mean ±S.E.M.
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FAK inhibition alters NSCLC cell migration on 2D and 3D.
FAK phosphorylation is an essential downstream signal for integrin activation. To
further investigate how FAK phosphorylation plays a role in cancer cell migration,
we treated Hop62, A549, and H2030 lung cancer cells with PF-573228 (Cayman
#S2013), a FAK397 autophosphorylation inhibitor.
To determine the concertation of PF-573228 that did not kill Hop62 cells, an
Alamar Blue cell viability assay with varying concentrations (0-20µM) of PF573228 at 24, 48, and 72 hours was performed (Figure 11a). Next, Hop62 cells
were cultured on 2D and 3D with varying concentrations of PF-573228 (0-5µM)
to determine which concertation inhibits FAK397 phosphorylation (Figure 11b). In
Hop62 cells, PF-573228 significantly inhibited FAK397 phosphorylation at the 2.55µM range on 2D plastic and 5µM on 3D CDM.
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Figure 11. PF-573228 inhibits the autophosphorylation of FAK in Hop62
lung cancer cells.
Hop62 cells were treated with varying concentrations of the FAK inhibitor, PF573228. A) Alamar Blue readings were recorded 24, 48, and 72 hours following
treatment. B) Hop62 cells were plated on 2D, and 3D IMR90 derived matrix. The
cells were treated with varying concentrations of Saracatinib and collected 72
hours following treatment. Western blot analysis of the extracts was probed for pFAK, FAK, and GAPDH.
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To determine the concertation of PF-573228 that did not kill A549 cells, an
Alamar Blue cell viability assay with varying concentrations (0-20µM) of PF573228 at 24, 48, and 72 hours was performed (Figure 12a). Next, A549 cells
were cultured on 2D and 3D with varying concentrations of PF-573228 (0-10µM)
to determine which concertation inhibits FAK397 phosphorylation (Figure 11b). In
Hop62 cells, PF-573228 significantly inhibited FAK397 phosphorylation at the 510µM range on 2D and 3D (Figure12b).
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Figure 12. PF-573228 inhibits the autophosphorylation of FAK in A549 lung
cancer cells.
A549 cells were treated with varying concentrations of the FAK inhibitor, PF573228. A) Alamar Blue readings were recorded 24, 48, and 72 hours following
treatment. B) A549 cells were plated on 2D, and 3D IMR90 derived matrix. The
cells were treated with varying concentrations of Saracatinib and collected 72
hours following treatment. Western blot analysis of the extracts was probed for pFAK, FAK, and GAPDH.
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To assess the inhibition of FAK's effect on cancer cell migration, spheroid assays
were performed on 2D and 3D with multiple lung cancer cell lines and treated
with PF-573228 or not. Hop62 cell spheroids, treated with 5µM of PF-573228 or
a DMSO vehicle control, were cultured on 2D plastic and 3D IMR90-derived
matrix for 48 hours (Figure 13a). The migrational area of the spheroids was
measured and quantified via ImageJ. Hop62 spheroids treated with PF-573228
migrated significantly less on 3D but not 2D compared to the vehicle control
(Figure 13b).
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Figure 13. PF-573228 decreases the collective cell migration of Hop62 lung
cancer cells.
Hop62 spheroids were grown for four days and transferred to 2D plastic, and 3D
IMR90 derived ECM. The spheroids were treated with PF-573228 (5µM) or
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B)
Quantification of total migrated area relative to the area of the spheroid.
Statistical analysis performed by 2-way ANOVA was performed with multiple
comparisons, * p<0.05, ** p<0.01; Data presented as mean ±S.E.M.
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A549 cell spheroids, treated with 5µM of PF-573228 or a DMSO vehicle control,
were cultured on 2D plastic and 3D IMR90-derived matrix for 48 hours (Figure
14a). The migrational area of the spheroid was measured and quantified via
ImageJ. There was no statistically significant difference in the migration of A549
spheroids treated with PF-573228 on 2D or 3D (Figure 14b).
These results suggest inhibition of FAK397 phosphorylation's influence on cell
migration is cell condition (2Dv3D) and cell line (Hop62vA549vH2030)
dependent.
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Figure 14. PF-573228 does not impact the collective cell migration of A549
lung cancer cells.
A549 spheroids were grown for four days and transferred to 2D plastic, and 3D
IMR90 derived ECM. The spheroids were treated with PF-573228 (5µM) or
Vehicle (DMSO). A) Images were captured 48 hours after initial plating. B)
Quantification of total migrated area relative to the area of the spheroid.
Statistical analysis performed by 2-way ANOVA was performed with multiple
comparisons; Data presented as mean ±S.E.M.
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Co-cultured fibroblast migration is Src-independent on 3D.
The tumor microenvironment is composed of many different cell types. Of those
cell types, fibroblasts are the most important for ECM production and
degradation. To investigate how fibroblasts play a role in cancer cell migration,
spheroid assays were performed, culturing both cancer cells and fibroblasts
together. In a 1:5 Hop62: IMR90GFP ratio, co-cultured spheroids were created,
transferred to 2D and 3D, and cultured for 72 hours (Figure 15a). Light and
fluorescence microscopy photos were captured, then measured and quantified
using ImageJ. The cancer cells were not fluorescently labeled, but the fibroblasts
were, allowing for separate quantification between the cancer cell and fibroblast
migration. The area cancer cell migration was not significantly changed on 2D or
3D, but the area of fibroblast migration was significantly increased on 3D
compared to 2D (Figure 15b).

46

Figure 15. IMR90 lung fibroblasts co-cultured with A549 lung cancer cells
migrate more on 3D CDM.
Co-cultured spheroids consisting of A549 and GFP labeled IMR90 lung
fibroblasts in a 1:5 ratio, respectively, were grown for 4 days and transferred to
2D plastic or 3D IMR90 derived ECM. A) Pictures were taken 72 hours following
transfer (bright field on the left, fluorescence on the right). B) Quantification of
total migrated area relative to the area of spheroid Statistical analysis performed
by 2-way ANOVA was performed with multiple comparisons, ** p<0.01, ****
p<0.001; Data presented as mean ±S.E.M.
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We previously showed that treatment of an Src inhibitor, Saracatinib, significantly
reduced the migration of Hop62, A549, and H2030 cells on 2D and 3D. Because
we saw such a noticeable migrational and phenotypic difference in the migration
of co-cultured fibroblasts on 2D compared to 3D, we wanted to investigate the
impact of Src inhibition on our co-cultured system. First, we needed to determine
the concertation of Saracatinib that was not lethal to IMR90 cells. To do this, an
Alamar Blue cell viability assay with varying concentrations (0-20µM) of
Saracatinib at 24, 48, and 72 hours was performed (Figure 16a). Next, IMR90
cells were cultured on 2D and 3D with varying concentrations of Saracatinib (010µM) to determine which concertation inhibits Src phosphorylation (Figure 23b).
Saracatinib significantly inhibited Src phosphorylation from the 0.6-10µM range in
IMR90 cells on both 2D and 3D (Figure 16b).
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Figure 16. Saracatinib inhibits Src phosphorylation in IMR90 lung
fibroblasts.
IMR90 lung fibroblasts were treated with varying concentrations of Saracatinib.
A) Alamar Blue readings were recorded 24, 48, and 72 hours following treatment.
B) IMR90 lung fibroblasts were plated on 2D, and 3D IMR90 derived matrix. The
cells were treated with varying concentrations of Saracatinib and collected 72
hours following treatment. Western blot analysis of the extracts was probed for psrc, src, and GAPDH.
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To investigate how Src inhibition impacted the cancer cell and fibroblast
migration, a spheroid co-culture assay was performed. In a 1:5 A549: IMR90GFP
ratio, co-cultured spheroids, treated with 5µM of Saracatinib or DMSO vehicle,
were cultured on 2D and 3D for 72 hours (Figure 17a). Light and fluorescence
microscopy photos were captured, then measured and quantified using ImageJ.
The cancer cells were not fluorescently labeled, but the fibroblasts were, allowing
for separate quantification between the cancer cell and fibroblast migration
(Figure 17b). When treated with saracatinib, cancer cell and fibroblast migration
decreased on 2D and 3D. Untreated spheroid cancer cell migration did not differ
on 2D and 3D. However, fibroblast migration significantly increased on 3D
compared to 2D. This data suggests fibroblasts migrate more on 3D and in an
Src-dependent manner on 2D, but not 3D, when co-cultured with A549 cancer
cells.
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Figure 17. Saracatinib blocks the migration of IMR90 lung fibroblasts cocultured with A549 lung cancer cells on 2D but not 3D.
Co-cultured spheroids consisting of A549 and IMR90 lung fibroblasts in a 1:5
ratio, respectively, were grown for 4 days and transferred to 2D plastic or 3D
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or
Vehicle (DMSO). A) Pictures were taken 72 hours following transfer (bright field
on the left, fluorescence on the right). B) Quantification of total migrated area
relative to the area of the spheroid. Statistical analysis performed by 2-way
ANOVA was performed with multiple comparisons, ** p<0.01, **** p<0.001; Data
presented as mean ±S.E.M.
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In a 1:5 Hop62: IMR90GFP ratio, co-cultured spheroids, treated with 5µM of
Saracatinib, or DMSO vehicle, was cultured on 2D and 3D for 72 hours (Figure
18a). Light and fluorescence microscopy photos were captured, then measured
and quantified using ImageJ. The cancer cells were not fluorescently labeled, but
the fibroblasts were, allowing for separate quantification between the cancer cell
and fibroblast migration (Figure 18b). When treated with saracatinib, cancer cell
migration was significantly decreased on 2D and appeared to decrease on 3D.
However, fibroblast migration significantly decreased on 3D but not 2D.
Untreated spheroid cancer cell migration did not differ on 2D and 3D. However,
fibroblast migration significantly increased on 3D compared to 2D. This data
suggests fibroblasts migrate more on 3D and in an Src-dependent manner on 2D
when co-cultured with Hop62 cancer cells.
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Figure 18. Saracatinib blocks the migration of IMR90 lung fibroblasts cocultured with Hop62 lung cancer cells on 2D but not 3D.
Co-cultured spheroids consisting of Hop62 and IMR90 lung fibroblasts in a 1:5
ration, respectively, were grown for 4 days and transferred to 2D plastic or 3D
IMR90 derived ECM. The spheroids were treated with Saracatinib (5µM) or
Vehicle (DMSO). A) Pictures were taken 72 hours following transfer (bright field
on the left, fluorescence on the right). B) Quantification of total migrated area
relative to the area of the spheroid. Statistical analysis performed by 2-way
ANOVA was performed with multiple comparisons, ** p<0.01, **** p<0.001; Data
presented as mean ±S.E.M.
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To investigate fibroblast migration independently of cancer cells on 2D, IMR90
fibroblasts were cultured at a low density on 2D and treated with Saracatinib or
not (Figure 19a and b). Treatment with Saracatinib significantly decreased
fibroblast displacement, acceleration, and speed on 2D (Figure 19c).
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Figure 19. Saracatinib impacts the single cell migration of IMR90 lung
fibroblasts on 2D.
IMR90 cells were plated at a low concentration on 2D plastic. Time-lapse
imaging was recorded, imaging every 15 minutes for 24 hours. IMR90s were
treated with either A) Vehicle (DMSO) or B) Saracatinib (5µM) C) Single-cell
speed, distance, and acceleration were recorded. Statistical analysis performed
by 2-way ANOVA was performed with multiple comparisons. Statistical analysis
performed by 2-way ANOVA was performed with multiple comparisons, *
p<0.05** p<0.01, **** p<0.001; Data presented as mean ±S.E.M.
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To investigate fibroblast migration independently of cancer cells on 3D, IMR90
fibroblasts were cultured at a low density on 3D and treated with Saracatinib or
not (Figure 20a and b). Treatment with Saracatinib did not significantly decrease
fibroblast displacement, acceleration, or speed on 3D (Figure 20c).
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Figure 20. Saracatinib does not impact the single cell migration of IMR90
lung fibroblasts on 3D.
IMR90 cells were plated at a low concentration on 3D IMR90 derived ECM.
Time-lapse imaging was recorded, imaging every 15 minutes for 24 hours.
IMR90s were treated with either A) Vehicle (DMSO) or B) Saracatinib (5µM) C)
Single-cell speed, distance, and acceleration were recorded. Statistical analysis
performed by 2-way ANOVA was performed with multiple comparisons.
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DISCUSSION
In this study, we investigated the role of integrin signaling, specifically Src,
in the context of NSCLC cell and fetal lung fibroblast migration on fetal lung
fibroblast-derived extracellular matrix. Our lab has previously demonstrated that
lung cancer cells alter their migration and integrin signaling on 3D cell-derived
matrix compared to 2D plastic [30]. Historically, cancer cell migration has been
studied in vitro utilizing plastic dishes. Here, we use a system using cell-derived
matric as a more physiologically relevant cell culture method and study the
interaction between cancer cells and the extracellular matrix (ECM). Fibroblasts
are the primary ECM producers and remodelers. This study highlighted the
differential cancer cell and fibroblast migration on 2D and 3D while perturbing
integrin signaling.
Schertzer et al. demonstrated that the single cell migration of cancer cells
is differentially altered on 2D and 3D. Furthermore, Src and FAK phosphorylation
was increased in NSCLC cells cultured on 3D. To further investigate this
phenotype, we developed a collective cell spheroid migration assay on 2D plastic
and 3D CDM. In multiple cell lines, collective cell migration was increased on 3D
CDM (Figures 1 and 2), suggesting that the ECM influenced cancer cell
migration. To increase scientific rigor, a scratch wound assay on 2D and 3D
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CDM was performed using A549 NSCLC cells (Figure 3), where collective cell
migration increased on 3D CDM. This data suggested that culturing NSCLC cells
on 3D CDM influenced collective cancer cell migration.
As previously stated, our group has shown that Src and FAK signaling is
increased in NSCLC cells cultured on 3D CDM. Src and FAK's role in cell
adhesion and migration is well documented [17]. Saracatinib is a welldocumented Src inhibitor [36], as well as a known inhibitor of EGFR and Abl, and
has been tested in multiple clinical trials but failed due to lack and efficacy and
harsh side effects. Regardless of the failed trials, Saracatinib is a potent Src
inhibitor. To investigate how inhibiting Src impacts NSCLC collective cell
migration, spheroid assays were performed with multiple NSCLC cell lines on 2D
and 3D treating with 5µM Saracatinib or DMSO vehicle (Figures 8-10). Inhibition
of Src completely blocked collective cell migration regardless of cell culture
conditions or cell line. PF-573228 inhibits the phosphorylation of FAK at its 397
autophosphorylation site. To investigate how inhibiting FAK397 phosphorylation
impacts NSCLC collective cell migration, spheroid assays were performed with
Hop62 and A549 NSCLC cell lines on 2D and 3D, and treated with 5µM PF573228 or DMSO vehicle (Figures 8-9). Interestingly enough, Hop62 collective
cell migration was decreased by PF-573228 on 3D, but not 2D. However, A549
collective cell migration was not affected by PF-573228 treatment regardless of
the condition. This data suggested that Src plays a more critical role in cancer
cell migration than FAK.
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Fibroblasts are among the most abundant cell types in the tumor
microenvironment and are responsible for remodeling and producing ECM. We
developed a system to co-culture cancer cells and fibroblasts together to create
co-cultured spheroids. When monitoring collective cell migration of A549-IMR90
co-cultured spheroids, IMR90 fibroblast migration was significantly increased on
3D compared to 2D. This data suggests that when IMR90 cells interact with the
cell-derived ECM, migrational phenotypes are enhanced. Because inhibiting Src
completely blocked the collective cell migration of cancer cells, we wanted to
investigate co-cultured spheroid migration when Src is inhibited with Saracatinib.
Interestingly enough, Saracatinib decreased cancer cell migration regardless of
conditions, where fibroblast migration was also decreased, but not to the same
extent. Compared to the cancer cells, the fibroblasts migrated significantly more
even when treated with Saracatinib. This data suggested that fibroblasts
migrated in a more Src-independent manner than cancer cells on 3D CDM.
Because we saw a difference in the cancer cell and fibroblast migration
when treated with Saracatinib, we investigated the migration of fibroblasts on 2D
and 3D, treated with Saracatinib or DMSO vehicle, independently of cancer cells
via single cell tracking. When treated with Saracatinib, fibroblast speed,
acceleration, and distance were significantly different between the vehicle-treated
group on 2D, but there was no difference between groups on 3D. This result
further supported our hypothesis that fibroblasts migrated in an Src-independent
manner on 3D CDM.
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It is well understood that fibroblasts play a critical role in facilitating cancer
cell metastasis [37]. This study is crucial in understanding how fibroblasts
migrate in the presence of cancer cells and not. Our results suggest that cancer
cells cultured on 3D cell-derived matrix migrate in a Src-dependent manner while
fibroblasts do not. These findings are important because they may explain why
Src inhibitors, such as Saracatinib, may have failed clinical trials due to
effectiveness. It is also important to note that we see the differences in modes of
migration of fibroblasts on 2D compared to 3D cell-derived matrix, a model
proposed to be more physiologically relevant. Understanding the mechanisms of
migration of cancer cells and fibroblasts when interacting with the ECM may be
crucial in targeting cancer metastasis.
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SUMMARY
Lung cancer is the most lethal type of cancer in males and females
primarily due to its metastatic spread. There has yet to be FDA-approved
treatment to treat lung cancer metastasis. To approach this knowledge gap, we
investigated the interactions between multiple components of the tumor
microenvironment. To this extent, we established a cell culture system that
mimics physiological conditions. Briefly, fibroblasts are cultured at confluence,
decellularized on the dish, and what's left behind is a 3D fibroblast-deposited
matrix. Utilizing this system allows us to study the interaction between NSCLC
cells and fibroblast-derived ECM.
When NSCLC cells are cultured on a fibroblast-derived matrix, their
velocity, directionality, and displacement increase. To investigate cancer cell
migration, we performed spheroid and scratch wound assays. Our results
revealed that cancer cell migration increased on 3D in multiple cell lines and
multiple migration assays. Because SRC signaling increased in cancer cells
cultured on 3D, we pharmacologically inhibited SRC in our spheroid assay.
Inhibiting SRC significantly decreased migration regardless of culture conditions.
To further investigate how fibroblasts impact cancer cell migration, co-cultured
spheroid assays were performed. Fibroblast migration increased on 3D, but
cancer cell migration did not. We treated the co-cultured spheroids with an SRC
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inhibitor. To our surprise, fibroblast migration decreased on 2D but not 3D. These
studies demonstrate that cancer cells and fibroblasts migrated through different
mechanisms on 3D fibroblast-derived matrix. Future studies will investigate the
specific mechanisms by which cancer cells and fibroblasts migrate on 3D
fibroblast-derived matrix.
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